Pre-Market Technical Scan on Biotech Equities -- Diffusion Pharma, Dynavax Technologies, Edge Therapeutics, and Editas Medicine
NEW YORK, May 1, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on DFFN, DVAX, EDGE, and EDIT which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, April 30, 2018, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,066.27, down 0.75%; the Dow Jones Industrial Average edged 0.61% lower, to finish at 24,163.15; and the S&P 500 closed at 2,648.05, down 0.82%. This Tuesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), and Editas Medicine Inc. (NASDAQ: EDIT). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Monday, shares in Charlottesville, Virginia headquartered Diffusion Pharmaceuticals Inc. recorded a trading volume of 147,849 shares. The stock ended the session flat at $0.55. The Company's shares have gained 0.73% in the last month. The stock is trading below its 50-day moving average by 8.81%. Moreover, shares of Diffusion Pharma, which develops small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action, have a Relative Strength Index (RSI) of 46.00. Get the full research report on DFFN for free by clicking below at:
Berkeley, California headquartered Dynavax Technologies Corp.'s stock closed the day 7.38% lower at $16.95 with a total trading volume of 1.37 million shares. The Company's shares have advanced 200.00% over the last twelve months. The stock is trading below its 50-day moving average by 6.55%. Additionally, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have an RSI of 40.65. Free research on DVAX can be accessed at:
Shares in Berkeley Heights, New Jersey headquartered Edge Therapeutics Inc. recorded a trading volume of 1.97 million shares, which was above their three months average volume of 1.55 million shares. The stock ended yesterday's trading session 5.17% lower at $1.10. The stock is trading below its 50-day moving average by 88.29%. Furthermore, shares of Edge Therapeutics, which discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions, have an RSI of 20.96. Sign up today for the free research report on EDGE at:
Cambridge, Massachusetts-based Editas Medicine Inc.'s stock finished Monday's session 4.79% lower at $31.40 with a total trading volume of 1.04 million shares. The Company's shares have advanced 66.58% in the past twelve months. The stock is trading above its 200-day moving average by 13.95%. Additionally, shares of Editas Medicine, which operates as a genome editing company, have an RSI of 39.81. Wall St. Equities' research coverage also includes the downloadable free report on EDIT at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Tom Johnson, email@example.com
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----diffusion-pharma-dynavax-technologies-edge-therapeutics-and-editas-medicine-300639880.html
SOURCE Wall St. Equities